My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Login
Register
money
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Menu
Research
My Stocks
Tools
Recent
Markets
Analyst Color
Tesla Analysts Brace For Q3 Sales Beat, Rivian Loses A Bull, Canoo Drives Across The Atlantic And More: Biggest EV Stories Of The Week
Tesla stock's resurgence and China stimulus that perked up startups from the country, added to the buoyancy imparted by the broader market strength.
This Analyst Sees More Than 25% Upside In Uber Thanks To Increased Food Delivery Penetration
Oppenheimer raises Uber's price target to $95 and maintains Outperform rating. Survey shows potential for new user acquisition. Delivery trends also favorable.
BlackBerry's Path To Profitability In Question, Analyst Cites Cybersecurity Struggles and Sluggish IoT Growth
BlackBerry stock plunges on upbeat Q2 report, beats revenue and EPS estimates with strength in IoT and cybersecurity. RBC reiterates Sector Perform with $3 price target.
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer option. Analysts project peak sales of up to $5 billion if approved for additional indications.
ICE's Resilient Business Model and Technological Advancements Drive an Outperform Rating - Here's Why
Analyst initiates coverage on ICE at Outperform, with $200 price target. Expects double-digit growth in mortgage tech, digitization benefits for ICE Bonds & Indices, and HSD-LDD income growth.
Tesla 'Mojo Is Back,' Tech Analyst Dan Ives Says Ahead Of Q3 Deliveries
Wedbush tech analyst Dan Ives said Friday he expects the Tesla's upcoming delivery figures to beat the Street's expectations.
Chesapeake Energy Set To Become Largest Natural Gas Producer In US, Says Analyst
Chesapeake Energy is to be merged with Southwestern Energy to become the largest gas producer. Roth Capital analyst assigns Buy rating on upside to gas prices.
Accenture Is A 'Key Beneficiary Of' GenAI: Analysts Raise Forecasts After Q4 Results
Accenture reported upbeat Q4 results. Analysts bullish on the company's GenAI bookings and consider guidance as conservative. Price targets raised.
Costco's Strong Q4 Performance Sparks Mixed Analyst Reactions As Stock Slides
Costco's reported Q4 earnings beat on strong sales and gross margin expansion. Some analysts warn of earnings growth moderating ahead.
Micron's AI-Driven HBM Demand and Data Center Growth to Fuel Stock Upside, Analysts Say
NASDAQ: MU stock rose after Micron reported strong Q4 results, beating revenue and EPS estimates. Analysts raise price targets, expect continued growth.
Nordstrom Downgraded: Analyst Highlights Consumer Pressure And Potential M&A Impact
KeyBanc downgraded Nordstrom to Sector Weight, citing go-private deal speculation and mixed outlook amid consumer pressures and holiday promotions.
GE Vernova Set For $2.5B Free Cash Flow By 2026 Amid Energy Transition Boom, Bullish Analyst Says
Analyst initiates coverage on GEV with Buy rating and $300 price target, citing strong position in energy transition and growth potential.
Disney's Streaming Surge, Epic Games Deal Among Key Growth Drivers, Says Analyst
Needham analyst reiterates Buy rating for Disney with $110 price target based on DTC breakeven in 2024, new subscribers, investments, cash flow, and content value.
Meta's AI Breakthroughs Dominate Connect Event As Analyst Highlights Affordable Mixed-Reality Push
Meta's AI and AR advancements excite investors and tech enthusiasts. Recent events showcase their ambition to shape computing's future.
Salesforce Analyst Sees AI As A Tailwind, Stakeholders 'Fed Up' With Dual Mandate
Salesforce can maintain 10% growth for a couple of years, but there's a call for innovative products to sustain long-term expansion.
Palantir Bull Says AI Platform Will Be Valuation Changer Heading Into 2025, Calls For Incremental 20% Upside For Stock
A bullish analyst is extremely positive about Palantir's AIP platform and its adoption by enterprises.
Expect Healthy Online Spending This Holiday Season, Says Analyst: What To Know
BofA Securities says U.S. consumers are focused on value and sees Amazon and Walmart as well-positioned in the e-commerce industry reap the benefits heading into a holiday season of healthy consumer spending.
Fox Stock Thrives On Sports, Politics Strategy: Analyst Says It Will 'Weather Secular Headwinds'
A Fox analyst raises the price target ahead of the 2024 election with the media company set to benefit from politics and sports.
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139 price target.
What's In Store For Nike In Q1? Analyst Highlights China Vs. North America Trends
Goldman Sachs maintains a Buy rating on Nike, anticipating healthy Q1 results but cautious on growth prospects amid mixed signals from China.
Why Is Global Payments Stock Diving On Wednesday?
Global Payments shares down on weaker FY25 EPS growth forecast. Company to return $7.5B to shareholders in next 3 years.
China's Stimulus Sparks Optimism: 3 Large-Cap Stocks With Analyst Buy Ratings
China's economic stimulus boosts markets with $140B injected into economy: JD, TCOM, BABA stocks have 37%-42% upside according to analysts.
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to Amgen's obesity data later this year.
Philip Morris Analyst Raises Forecasts Ahead Of Q3 Earnings, But 'Consumer Elasticities Remain A Risk'
Philip Morris International will report Q3 results on Oct 22. Analyst expects the Marlboro parent company to report 7.6% revenue growth.
Visa Stock Has Near-Term 'Overhang' From DOJ Antitrust Lawsuit: Analyst Picks 3 Stocks To Benefit
A DOJ lawsuit against Visa could hurt the company's market share and see competitors gain, an analyst said.
Analyst Ditches Automakers For Auto Dealers, Parts Companies
Analysts at Morgan Stanley sparked a shakeup across auto stocks Wednesday as the firm moved to the sidelines on automakers and turned more positive on dealers and parts companies.
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval in April.
DoorDash Positioned As Clear Market Share Gainer With Growth In Grocery And Ads, Analyst Says, Upgrades Stock
KeyBanc analyst upgrades DoorDash, Inc (DASH) stock to Overweight with $177 price target, citing strong growth potential in food delivery and new verticals.
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on company's bottom line.
Mortgage Demand Soars As Fed Interest Rate Cut Fuels Housing Market Revival: 'Next Spring Could See A Real Rebound'
US homeowners and buyers were waiting for the Federal Reserve's move to boost the mortgage market. A 50-basis-point rate cut led to a surge in applications.